News
JP Morgan Maintains Overweight on Amicus Therapeutics, Lowers Price Target to $19
18 Mar 24
News, Price Target, Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Amicus Therapeutics, Maintains $22 Price Target
29 Feb 24
News, Price Target, Reiteration, Analyst Ratings
Earnings Scheduled For February 28, 2024
28 Feb 24
Earnings
Press releases
WuXi Biologics Reports Solid 2023 Annual Results
26 Mar 24
Earnings, Press Releases
Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2024
1 Mar 24
News, Press Releases
Amicus Therapeutics Announces Full-Year 2023 Financial Results and Corporate Updates
28 Feb 24
Earnings, Press Releases
Amicus Therapeutics Receives the 2024 New Treatment Award for Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) at the 20th Annual WORLDSymposium™
8 Feb 24
Press Releases
Amicus Therapeutics Announces Presentations and Posters at the 20th Annual WORLDSymposium™ 2024
1 Feb 24
News, Press Releases